BMK1/ERK5 is a novel regulator of angiogenesis by destabilizing hypoxia inducible factor 1α

Xinchun Pi, Gwenaele Garin, Liang Xie, Qinlei Zheng, Heng Wei, Jun-ichi Abe, Chen Yan, Bradford C. Berk

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Big MAP kinase 1 (BMK1 or ERK5) is a key mediator of endothelial cell (EC) function as shown by impaired embryonic angiogenesis and vascular collapse in BMK1 knockout mice. Hypoxia inducible factor 1α (HIF1α), a potent mediator of angiogenesis, is positively regulated by the MAP kinases, ERK1/2. Because BMK1 deficiency is associated with impaired angiogenesis we hypothesized that BMK1 might regulate HIF1α. To test this hypothesis, bovine lung microvascular ECs (BLMECs) were transfected with HIF1α and BMK1 cDNAs, and stimulated by hypoxia. HIF1α activity was measured by a reporter gene assay in which luciferase expression was driven by HIF1α activation. Hypoxia (1% O2, 24 hours) stimulated HIF1α activity by 5.1 ± 0.6 fold. In the presence of dominant negative (DN)-BMK1, which inhibited BMK1 activity, hypoxia induced HIF1α activity was enhanced significantly to 6.4 ± 0.4 fold. BMK1 activation by constitutively active (CA)-MEKS inhibited HIF1α activity by 46 ± 4%, suggesting BMK1 functions as a negative regulator of HIF1α activation. Activation of BMK1 reduced HIF1α protein levels. Ubiquitination inhibitors (30 μmol/L ALLN, 2 μmol/L lactacystin, or 100 nmol/L MG132) reduced the BMK1-mediated effect on HIF1α expression by >80%, suggesting that BMK1 stimulated HIF1α proteolysis. The negative effect of BMK1 on HIF1α was functionally important because transfection with CA-MEK5 significantly decreased EC migration by 68 ± 10%, and inhibited angiogenesis (in vitro Matrigel assay) by 76 ± 7%. In summary, BMK1 is a novel negative regulator of HIF1α and angiogenesis by increasing HIF1α ubiquitination and inhibiting HIF1α activity in endothelial cells.

Original languageEnglish (US)
Pages (from-to)1145-1151
Number of pages7
JournalCirculation Research
Volume96
Issue number11
DOIs
StatePublished - Jun 10 2005

Fingerprint

Hypoxia-Inducible Factor 1
Endothelial Cells
Ubiquitination
Mitogen-Activated Protein Kinase 7
Mitogen-Activated Protein Kinase 1

Keywords

  • Angiogenesis
  • Big MAP kinase 1
  • Hypoxia inducible factor 1α

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

BMK1/ERK5 is a novel regulator of angiogenesis by destabilizing hypoxia inducible factor 1α. / Pi, Xinchun; Garin, Gwenaele; Xie, Liang; Zheng, Qinlei; Wei, Heng; Abe, Jun-ichi; Yan, Chen; Berk, Bradford C.

In: Circulation Research, Vol. 96, No. 11, 10.06.2005, p. 1145-1151.

Research output: Contribution to journalArticle

Pi, Xinchun ; Garin, Gwenaele ; Xie, Liang ; Zheng, Qinlei ; Wei, Heng ; Abe, Jun-ichi ; Yan, Chen ; Berk, Bradford C. / BMK1/ERK5 is a novel regulator of angiogenesis by destabilizing hypoxia inducible factor 1α. In: Circulation Research. 2005 ; Vol. 96, No. 11. pp. 1145-1151.
@article{3f4ab4248a9d4b14a695ac18a9d4f0a6,
title = "BMK1/ERK5 is a novel regulator of angiogenesis by destabilizing hypoxia inducible factor 1α",
abstract = "Big MAP kinase 1 (BMK1 or ERK5) is a key mediator of endothelial cell (EC) function as shown by impaired embryonic angiogenesis and vascular collapse in BMK1 knockout mice. Hypoxia inducible factor 1α (HIF1α), a potent mediator of angiogenesis, is positively regulated by the MAP kinases, ERK1/2. Because BMK1 deficiency is associated with impaired angiogenesis we hypothesized that BMK1 might regulate HIF1α. To test this hypothesis, bovine lung microvascular ECs (BLMECs) were transfected with HIF1α and BMK1 cDNAs, and stimulated by hypoxia. HIF1α activity was measured by a reporter gene assay in which luciferase expression was driven by HIF1α activation. Hypoxia (1{\%} O2, 24 hours) stimulated HIF1α activity by 5.1 ± 0.6 fold. In the presence of dominant negative (DN)-BMK1, which inhibited BMK1 activity, hypoxia induced HIF1α activity was enhanced significantly to 6.4 ± 0.4 fold. BMK1 activation by constitutively active (CA)-MEKS inhibited HIF1α activity by 46 ± 4{\%}, suggesting BMK1 functions as a negative regulator of HIF1α activation. Activation of BMK1 reduced HIF1α protein levels. Ubiquitination inhibitors (30 μmol/L ALLN, 2 μmol/L lactacystin, or 100 nmol/L MG132) reduced the BMK1-mediated effect on HIF1α expression by >80{\%}, suggesting that BMK1 stimulated HIF1α proteolysis. The negative effect of BMK1 on HIF1α was functionally important because transfection with CA-MEK5 significantly decreased EC migration by 68 ± 10{\%}, and inhibited angiogenesis (in vitro Matrigel assay) by 76 ± 7{\%}. In summary, BMK1 is a novel negative regulator of HIF1α and angiogenesis by increasing HIF1α ubiquitination and inhibiting HIF1α activity in endothelial cells.",
keywords = "Angiogenesis, Big MAP kinase 1, Hypoxia inducible factor 1α",
author = "Xinchun Pi and Gwenaele Garin and Liang Xie and Qinlei Zheng and Heng Wei and Jun-ichi Abe and Chen Yan and Berk, {Bradford C.}",
year = "2005",
month = "6",
day = "10",
doi = "10.1161/01.RES.0000168802.43528.e1",
language = "English (US)",
volume = "96",
pages = "1145--1151",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - BMK1/ERK5 is a novel regulator of angiogenesis by destabilizing hypoxia inducible factor 1α

AU - Pi, Xinchun

AU - Garin, Gwenaele

AU - Xie, Liang

AU - Zheng, Qinlei

AU - Wei, Heng

AU - Abe, Jun-ichi

AU - Yan, Chen

AU - Berk, Bradford C.

PY - 2005/6/10

Y1 - 2005/6/10

N2 - Big MAP kinase 1 (BMK1 or ERK5) is a key mediator of endothelial cell (EC) function as shown by impaired embryonic angiogenesis and vascular collapse in BMK1 knockout mice. Hypoxia inducible factor 1α (HIF1α), a potent mediator of angiogenesis, is positively regulated by the MAP kinases, ERK1/2. Because BMK1 deficiency is associated with impaired angiogenesis we hypothesized that BMK1 might regulate HIF1α. To test this hypothesis, bovine lung microvascular ECs (BLMECs) were transfected with HIF1α and BMK1 cDNAs, and stimulated by hypoxia. HIF1α activity was measured by a reporter gene assay in which luciferase expression was driven by HIF1α activation. Hypoxia (1% O2, 24 hours) stimulated HIF1α activity by 5.1 ± 0.6 fold. In the presence of dominant negative (DN)-BMK1, which inhibited BMK1 activity, hypoxia induced HIF1α activity was enhanced significantly to 6.4 ± 0.4 fold. BMK1 activation by constitutively active (CA)-MEKS inhibited HIF1α activity by 46 ± 4%, suggesting BMK1 functions as a negative regulator of HIF1α activation. Activation of BMK1 reduced HIF1α protein levels. Ubiquitination inhibitors (30 μmol/L ALLN, 2 μmol/L lactacystin, or 100 nmol/L MG132) reduced the BMK1-mediated effect on HIF1α expression by >80%, suggesting that BMK1 stimulated HIF1α proteolysis. The negative effect of BMK1 on HIF1α was functionally important because transfection with CA-MEK5 significantly decreased EC migration by 68 ± 10%, and inhibited angiogenesis (in vitro Matrigel assay) by 76 ± 7%. In summary, BMK1 is a novel negative regulator of HIF1α and angiogenesis by increasing HIF1α ubiquitination and inhibiting HIF1α activity in endothelial cells.

AB - Big MAP kinase 1 (BMK1 or ERK5) is a key mediator of endothelial cell (EC) function as shown by impaired embryonic angiogenesis and vascular collapse in BMK1 knockout mice. Hypoxia inducible factor 1α (HIF1α), a potent mediator of angiogenesis, is positively regulated by the MAP kinases, ERK1/2. Because BMK1 deficiency is associated with impaired angiogenesis we hypothesized that BMK1 might regulate HIF1α. To test this hypothesis, bovine lung microvascular ECs (BLMECs) were transfected with HIF1α and BMK1 cDNAs, and stimulated by hypoxia. HIF1α activity was measured by a reporter gene assay in which luciferase expression was driven by HIF1α activation. Hypoxia (1% O2, 24 hours) stimulated HIF1α activity by 5.1 ± 0.6 fold. In the presence of dominant negative (DN)-BMK1, which inhibited BMK1 activity, hypoxia induced HIF1α activity was enhanced significantly to 6.4 ± 0.4 fold. BMK1 activation by constitutively active (CA)-MEKS inhibited HIF1α activity by 46 ± 4%, suggesting BMK1 functions as a negative regulator of HIF1α activation. Activation of BMK1 reduced HIF1α protein levels. Ubiquitination inhibitors (30 μmol/L ALLN, 2 μmol/L lactacystin, or 100 nmol/L MG132) reduced the BMK1-mediated effect on HIF1α expression by >80%, suggesting that BMK1 stimulated HIF1α proteolysis. The negative effect of BMK1 on HIF1α was functionally important because transfection with CA-MEK5 significantly decreased EC migration by 68 ± 10%, and inhibited angiogenesis (in vitro Matrigel assay) by 76 ± 7%. In summary, BMK1 is a novel negative regulator of HIF1α and angiogenesis by increasing HIF1α ubiquitination and inhibiting HIF1α activity in endothelial cells.

KW - Angiogenesis

KW - Big MAP kinase 1

KW - Hypoxia inducible factor 1α

UR - http://www.scopus.com/inward/record.url?scp=20444489156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444489156&partnerID=8YFLogxK

U2 - 10.1161/01.RES.0000168802.43528.e1

DO - 10.1161/01.RES.0000168802.43528.e1

M3 - Article

C2 - 15879308

AN - SCOPUS:20444489156

VL - 96

SP - 1145

EP - 1151

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 11

ER -